We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | NASDAQ:RIGL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 6.09% | 1.22 | 1.16 | 1.26 | 1.22 | 1.16 | 1.18 | 791,587 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Rigel Pharmaceuticals Inc. on Friday said the U.S. Food and Drug Administration declined the company's request for an emergency-use authorization for fostamatinib to treat hospitalized patients suffering from Covid-19.
The South San Francisco, Calif., biotechnology company said the agency determined that clinical data it submitted in late May from a phase 2 study are insufficient to support the authorization at this time.
Rigel said the FDA noted that it remains committed to working with the company in developing fostamatinib for Covid-19.
Rigel is currently conducting a larger Phase 3 trial of fostamatinib in hospitalized Covid-19 patients, and the company said it would resubmit its application for an emergency-use authorization if that study meets its primary endpoints.
Shares of Rigel, which closed Thursday at $4.13, fell nearly 10% in premarket trading Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 13, 2021 08:00 ET (12:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Rigel Pharmaceuticals Chart |
1 Month Rigel Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
